MENU
+Compare
CUE
Stock ticker: NASDAQ
AS OF
Nov 13 closing price
Price
$0.62
Change
-$0.05 (-7.46%)
Capitalization
46.91M

CUE Cue Biopharma Forecast, Technical & Fundamental Analysis

Cue Biopharma Inc is a clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
CUE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for CUE with price predictions
Nov 12, 2025

Momentum Indicator for CUE turns negative, indicating new downward trend

CUE saw its Momentum Indicator move below the 0 level on October 22, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In of the 95 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CUE moved out of overbought territory on October 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for CUE turned negative on October 23, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

CUE moved below its 50-day moving average on November 03, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CUE crossed bearishly below the 50-day moving average on October 31, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CUE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CUE entered a downward trend on November 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CUE advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

CUE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.583) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (5.441) is also within normal values, averaging (322.723).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CUE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CUE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CUE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

CUE is expected to report earnings to rise 42.86% to -10 cents per share on March 24

Cue Biopharma CUE Stock Earnings Reports
Q4'25
Est.
$-0.10
Q3'25
Beat
by $0.02
Q2'25
Beat
by $0.05
Q1'25
Missed
by $0.01
Q4'24
Missed
by $0.04
The last earnings report on November 12 showed earnings per share of -7 cents, beating the estimate of -8 cents. With 3.44M shares outstanding, the current market capitalization sits at 46.91M.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
40 Guest Street
Phone
+1 617 949-2680
Employees
53
Web
https://www.cuebiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MEDIF0.05N/A
+0.13%
Medipharm Labs Corporation
SFOSF3.30N/A
N/A
Shanghai Fosun Pharmaceutical Group Co Ltd
SKSJF6.51N/A
N/A
Shinko Shoji Co Ltd.
ZEOOF9.35N/A
N/A
Zeon Corp.
NEWEN100.04-24.93
-19.95%
New England Power Co.

CUE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CUE has been loosely correlated with SGMT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CUE jumps, then SGMT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CUE
1D Price
Change %
CUE100%
-2.25%
SGMT - CUE
43%
Loosely correlated
+3.76%
CRBU - CUE
41%
Loosely correlated
+0.89%
ABCL - CUE
39%
Loosely correlated
-1.00%
ARWR - CUE
37%
Loosely correlated
-0.19%
IMNM - CUE
37%
Loosely correlated
-0.51%
More